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A B S T R A C T
Background: Intra-pleural bacteria are eﬀective pleurodesis agents in malignant pleural eﬀusions. However,
their relationship with survival is unclear.
Objectives: We undertook a comprehensive, structured evaluation of survival outcomes in adults with malignant
pleural eﬀusions treated with intra-pleural bacterial products.
Data sources: Medline, Embase, Cochrane library, Clinical Trials Registers and Open Grey.
Study eligibility criteria, participants, and interventions: Randomised controlled trials and non-randomised com-
parative studies were included, if the population included adults with malignant pleural eﬀusions. Interventions
of interest were any intra-pleural bacterial product, compared with placebo, alternative intra-pleural drug, or no
treatment. Survival outcomes were collected.
Study appraisal and synthesis methods: Two reviewers independently screened studies for eligibility, assessed
papers for risk of bias and extracted data. Narrative synthesis was performed as high heterogeneity between
studies precluded meta-analysis.
Results: 631 studies were identiﬁed, of which 14 were included. All were at high or unclear risk of bias in at least
one domain. Six studies reported a survival beneﬁt associated with intra-pleural bacterial products, whilst 8
reported no diﬀerence. Non-randomised studies and studies published prior to 2000 were more likely to report
survival beneﬁts.
Limitations: There was high heterogeneity between studies, which limited the generalisability of ﬁndings.
Publication bias may have aﬀected the review as ﬁve full-text papers were unobtainable, and survival outcomes
were missing in a further ﬁve.
Conclusions: There is a lack of high quality evidence regarding the relationship between intra-pleural bacterial
products and survival.
Implications of key ﬁndings: Well-designed, prospective randomised trials are needed, to determine whether
intra-pleural bacterial products can improve survival in pleural malignancy.
PROSPERO registration number: CRD42017058067.
1. Background
Malignant pleural eﬀusions (MPE) arise as a result of primary
pleural tumours, i.e. malignant pleural mesothelioma (MPM), or me-
tastatic spread from distal tumours, most commonly lung cancer [1].
The presence of MPE usually reﬂects advanced or metastatic disease,
and consequently treatment is primarily palliative, with ﬂuid man-
agement a priority [2–4].
Administering an inﬂammatory agent into the pleural space to
achieve pleurodesis is an eﬀective way of controlling ﬂuid and im-
proving breathlessness, but has no eﬀect on the underlying disease
process. [1,3,5,6], Historically, pleurodesis was undertaken using bac-
terial products such as Corynebacterium] parvum, and in certain coun-
tries these products are still used [7–10]. Some clinicians believed these
products exerted an anti-tumour eﬀect alongside their pleurodesis
properties [11–13]. The hypothesis was based on evidence that MPE
were associated with local immune inhibition, and that survival cor-
related with the ability to maintain intra-pleural immune activity
[14–19]. Bacterial products were recognised as potent stimulators of
the immune response, and hence an early theory of immunotherapy
was developed. This was supported by observational studies that sug-
gested pleural infection was associated with longer survival following
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surgery for lung cancer [20–22].
The concept evolved through the 1970 s with clinical trials evalu-
ating the role of intra-pleural BCG after lung cancer surgery. Trial data
were conﬂicting, and the practice was not adopted into routine care
[23–27]. However, BCG found a role as an intra-vesical treatment for
bladder cancer, suggesting some anti-neoplastic activity [28].
Recently, interest in immunotherapy has resurfaced, and several
systemic immunotherapy products have been adopted into routine use
for other cancer types [29–35]. Interest in intra-pleural bacterial pro-
ducts has also risen, with agents such as Staphylococcus superantigen,
Lactobacillus casei and streptococcal preparations undergoing in-
vestigations in clinical studies [36–38].
To date, the literature on intra-pleural bacterial products and their
relationship with survival has not been systematically reviewed. We
aimed to undertake a comprehensive evaluation of the evidence, with
meta-analysis of RCT data if possible, to answer the question “Are intra-
pleural bacterial products associated with longer survival in adults with
MPE?”
2. Methods
2.1. Registration
The review was registered on PROSPERO International Prospective
Register of Systematic Reviews, registration CRD42017058067. A
summary of the protocol is available at https://www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42017058067.
2.2. Data sources
An electronic literature search was undertaken using MEDLINE
(1946 to Present), EMBASE (1974–2017 week 09), Cochrane Database
of Systematic Reviews, Cochrane CENTRAL Register of Controlled
Trials, International Clinical Trials Registry (ISRCTN), EU Clinical
Trials Register, US NIH Clinical Trials Register and Open Grey (System
for Information on Grey Literature in Europe – SIGLE).
Once the initial electronic search was complete, a manual search
was undertaken to review the references of included papers and sys-
tematic reviews, to ensure all relevant papers were captured.
2.3. Search strategy
The search strategy for each database is shown in Appendix A. The
strategy included exploded MeSH headings for MPE, combined with
keyword or title word searches for intra-pleural bacteria, im-
munotherapy and speciﬁc products. The initial search was performed
on 28/02/17 and was repeated on 22/02/18 to identify studies pub-
lished in the intervening year.
2.4. Eligibility criteria
2.4.1. Types of study
RCTs were included, as were non-randomised comparative studies.
Non-randomised studies included case-control studies, comparative
cohort studies and matched case series, prospective or retrospective.
Studies with no comparison group were excluded, as were informal
review articles, editorials, conference abstracts, animal or in vitro stu-
dies and studies where no abstract was available. Systematic reviews
were included and used to identify potentially eligible studies not
identiﬁed by the search.
Clinical trials registers were searched. If the timelines suggested the
trial had been completed but not reported, the authors were contacted
and asked to provide the data.
Research papers in all languages were included. Foreign language
papers were translated into English using an online translation service.
No date limitations were placed on the search.
2.4.2. Types of participants
Studies were eligible if they included adults with MPE due to any
underlying tumour. Studies were excluded if they included a mixed
population of benign and malignant eﬀusions, unless there was a clear
distinction in reporting the results for the two groups. Similarly, studies
that included participants with other eﬀusions (e.g. ascites) were ex-
cluded unless the results were reported separately for each eﬀusion
type. Studies that included a surgical cohort were excluded as pleural
involvement is usually a contra-indication for cancer surgery.
2.4.3. Types of interventions
The intervention was intra-pleural delivery of any bacterial product
including, but not limited to, Corynebacterium parvum, BCG,
Staphylococcus superantigen, Lactobacillus casei, OK432 and lipopoly-
saccharides. Studies in which bacterial preparations were delivered via
other methods were excluded. Studies assessing viral vectors, vaccine
therapy, fungal extracts or synthetic immunotherapies were excluded.
2.4.4. Types of comparators
Comparators included no treatment, placebo or alternative non-
bacterial intra-pleural product.
2.4.5. Types of outcomes
The outcome of interest was survival. Outcomes relating to pleural
eﬀusion size, pleural eﬀusion control or pleurodesis were not collected
as this data has been reviewed in a recent Cochrane meta-analysis [6].
If an article referred to unpublished data that may have met the elig-
ibility criteria, the authors were contacted and asked to provide raw
data.
2.4.6. Screening & study selection
The titles and abstracts of studies identiﬁed by the search were
screened for eligibility and potential studies obtained in full-text format
and reviewed.
2.4.7. Assessment of risk of bias
Included studies were assessed using the Cochrane risk of bias tool
[39].
2.4.8. Data extraction
Data were extracted from included studies using the form shown in
Appendix B. If a study stated in its methodology that data relevant to
the PICO criteria was collected, but did not report this data, the authors
were contacted and asked to provide the data.
Abstract screening, full-text review, risk of bias assessment and data
extraction were undertaken by two reviewers, independently.
Discrepancies were resolved by discussion, or by consultation with a
third party.
2.4.9. Data analysis
Odds ratios were calculated with 95% conﬁdence intervals (95% CI)
for proportional outcomes, where possible. Hazard ratios (and 95% CI)
were extracted for time to event data, or calculated using Cox
Proportional Hazards Model if suﬃcient data were available. Where
comparative statistics could not be calculated, simple descriptors were
reported with measures of variance as reported in the original studies.
Meta-analysis was planned if two or more RCTs were identiﬁed with
low risk of bias in the randomisation domain, provided the data were
comparable. Heterogeneity was expected to be high, therefore a
random eﬀects model was planned. Heterogeneity would be assessed
visually with Forest plots, and using the I2 statistic [40]. Where in-
suﬃcient data were available for meta-analysis, and for studies with a
high risk of bias, narrative synthesis was performed.
Univariable meta-regression and Fishers exact test for heterogeneity
were used to explore the relationship between study design, year of
publication, patient population and bacterial product studied and the
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likelihood of the study reporting a positive eﬀect.
3. Results
3.1. Literature search & eligibility
631 articles were identiﬁed by the search, once duplicates were
removed. Of these, 602 were excluded at screening, and 29 full-text
manuscripts were retrieved. 15 [41]articles were excluded at full-text
review: full-text was unavailable for 5; survival outcomes were not
reported, or not reported separately, in 6; 2 publications reported du-
plicate data (in both cases the paper with the least amount of data was
excluded); 1 paper had no data on pleural eﬀusions and 1 paper was a
review article. Thus 14 articles were included. The PRISMA diagram is
shown in Fig. 1. A list of papers excluded at full-text stage is available in
Appendix C, with reasons for exclusion.
3.2. Characteristics of included studies
Of 14 papers included, 8 were RCTs [7,37,38,42–46], and 6 were
non-randomised comparison studies, most commonly cohort studies
with historic comparators [13,36,41,47–49]. Studies were published
between 1979 and 2007, with 6 undertaken during or after 2000.
[36,41–43,46,47],Study characteristics of RCTs and non-randomised
studies are shown in Table 1 and Table 2 respectively.
The most frequent population was patients with MPE due to lung
cancer (all sub-types) [37,38,45,48,49], or non-small cell lung cancer
(NSCLC) [36,41–4346]. Other studies included patients with MPE due
to any underlying tumour [7,13], MPE due to MPM [47] and MPE
secondary to lung and gastrointestinal tumours [44].
Several bacterial products were used, including OK432 in 6 studies,
[38,41,42,44,46], Corynebacterium parvum in 3, [7,13,47], BCG cell
wall skeleton in 2, [48,49], and Lactobacillus casei [37], Staphylococcus
aureus superantigen [36], and Nocardia rubra cell wall skeleton [45] in
1 apiece. Comparators included intra-pleural chemotherapy,
[7,13,37,38,41,42,44–46], usual treatment, [48,49], talc poudrage
[36], or alternative pleurodesis agents [47]. One RCT compared two
doses of the same bacterial product [43]. Two studies employed a three-
arm design, comprising bacterial product alone, chemotherapy alone,
and bacteria/chemotherapy combination. [42,44]
3.3. Risk of bias assessment
Risk of bias was high or unclear in at least one domain for all stu-
dies, as shown in Table 3.
Half the included RCTs (4/8) were published prior to the develop-
ment of the Consolidated Standards of Reporting Trials (CONSORT)
guidance, and consequently much of the information required to assess
risk of bias was lacking. Information on random sequence allocation
and concealment of allocation was provided in only 3 trials. [37,38,44],
Information on blinding of participants and outcome assessments was
lacking in all but two RCTs. [37,45], Selective reporting and incomplete
outcome data were commonplace, with only three RCTs including all
participants in the ﬁnal analysis and reporting all outcomes stated in
the methodology. [42,43,46],
All non-randomised studies were at high risk of selection bias, as
well as high risk of performance and ascertainment bias, since none
were blinded. Although the latter two biases are less pertinent in the
context of an objective outcome measure such as survival, the lack of
blinding enabled selective reporting of outcomes, which introduced
further potential bias. All 6 non-randomised studies were at risk of
other biases or confounding, as described in Section 3.6.
3.4. Synthesis of results
Six of the fourteen included studies reported a survival beneﬁt as-
sociated with intra-pleural bacterial immunotherapy.
[13,36,37,45,48,49], This ranged from 2.5 months to 5.4 months from
the date of drug administration. However, no conﬁdence intervals were
reported so it was impossible to evaluate the precision of these esti-
mates. The remaining eight studies demonstrated no diﬀerence in sur-
vival between patients treated with intra-pleural bacteria and com-
parators. [7,38,41–44,46,47],
Only one paper provided a measure of variance for the survival
estimate, speciﬁcally 95% CI [36]. One paper provided patient-level
data, and survival analysis was undertaken by one of the reviewers
(ACB) [49]. No other measures of variance were available and requests
for raw data were unsuccessful, therefore meta-analysis was not pos-
sible. Additionally, high heterogeneity within and between populations,
interventions and comparators meant meta-analysis was inappropriate,
even using a random-eﬀects model. Consequently, narrative synthesis
Full text retrieved
29
Excluded at 
screening 
602
Excluded at full text review
15
Reasons:
Full text not available – 5
Survival outcomes not reported 
(authors contacted for raw 
data) – 6
Eo pleural eīusions – 1
Duplicate publication of data– 2
Review article - 1
Included in review
14
Identified through 
electronic database 
search - 666
Identified from grey 
literature & clinical 
trials registers - 336
Identified from 
manual search & 
snowballing - 7
Total screened, once 
duplicates removed
631
Fig. 1. PRISMA diagram for search and subsequent review.
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was undertaken.
3.5. Results of individual studies – randomised trials
Five RCTs investigated OK432, a heat- and penicillin-killed
Streptococcus pyogenes preparation. An initial dose-ﬁnding trial found
that 10 Klinische Einheit (KE) of OK432 was associated with longer
survival than a dose of 1KE (33.6 weeks vs 22.6 weeks) but inter-
pretation of these results is diﬃcult without a non-OK432 comparator
group [43].
Other trials compared OK432 with intra-pleural chemotherapy. The
most methodologically robust was a three-armed study that compared
OK432 at a dose of 0.2KE/kg with two diﬀerent intra-pleural che-
motherapy regimens in MPE secondary to NSCLC [46]. No survival
diﬀerence was seen across the three groups. Similarly, Luh et al found
no diﬀerence in survival between lung cancer patients treated with
intra-pleural mitomycin C or OK432 (10KE) [38]. This paper was at risk
of selective reporting, however, as outcomes were not stated a priori,
and some participants were excluded from the analysis due to early
death.
Ishida et al reported a trend towards longer survival in patients with
MPE secondary to NSCLC treated with 5KE of OK432 and intra-pleural
cisplatin, compared with OK432 alone or cisplatin alone [42]. Median
survival was 8.3 months in the combination arm, compared with 5
months for cisplatin and 4.3 months for OK432 alone. Statistical sig-
niﬁcance was not achieved (p= 0.55), however, the trial was under-
powered as only 49 patients participated – a sample size that was based
on time constraints rather than formally calculated.
The ﬁnal study to evaluate OK432 used diﬀerent combinations of
intra-venous and intra-pleural chemotherapy compared with varying
doses of OK432, alone or in combination with intra-pleural che-
motherapy [44]. The heterogeneity of regimens makes the results dif-
ﬁcult to interpret, and the use of an comparator with a proven survival
beneﬁt (intravenous chemotherapy) in one arm must be taken into
account when considering the results. No diﬀerence in survival was
seen between the chemotherapy and OK432 arms, however the com-
bination of OK432 and intra-pleural chemotherapy appeared to be as-
sociated with longer survival compared with OK432 alone (115 days vs
51 days). Given that intra-venous chemotherapy was given to a pro-
portion of the control arm, this result could be interpreted to mean
intra-pleural OK432 is as eﬀective as standard of care chemotherapy.
However, the lack of detail provided in the results and the fact the study
Table 1
Summary of randomised trials included in the review [7,37,38,42–46].
Abbreviations: 95% CI – 95% conﬁdence intervals, C. Parvum – Corynebacterium parvum, GI – gastro-
intestinal, HR – hazard ratio, i/p – intra-pleural, i/v – intravenous, KE – Klinische Einheit, kg – kilogram, mcg –
microgram, mg – milligram, MST – median survival time, MPE – malignant pleural eﬀusion, NS – non-sig-
niﬁcant, NSCLC – non-small cell lung cancer.
Table 2
Summary of non-randomised studies included in the review [13,36,41,47–49].
Abbreviations: 95% CI – 95% conﬁdence intervals, C. Parvum – Corynebacterium parvum, GI – gastrointestinal, HR
– hazard ratio, I/P – intra-pleural, I/V – intravenous, KE – Klinische Einheit, kg – kilogram, mcg – microgram, mg –
milligram, MST –median survival time, MPE –malignant pleural eﬀusion, NS – non-signiﬁcant, NSCLC – non-small
cell lung cancer.
*Survival analysis undertaken by reviewer (ACB).
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was not a formal non-inferiority design, make this likely to be an over-
interpretation.
Yamamura et al also combined intra-pleural chemotherapy with a
bacterial product, using Nocardia rubra cell wall skeleton in conjunc-
tion with doxorubicin, or doxorubicin alone in 68 participants with
MPE secondary to lung cancer [45]. The nocardia group had a median
survival of 266 days, compared with 190 days for single-agent doxor-
ubicin (p < 0.05). However, patients who died within 30 days of
randomisation were excluded from the analysis, risking attrition bias.
Furthermore this outcome was the result of sub-group analysis of data
from a larger trial in which multiple analyses were undertaken, without
pre-speciﬁcation in the analysis plan. Consequently reporting bias is
possible.
Another RCT randomised 95 participants with lung cancer MPE to
receive intra-pleural Lactobacillus casei and doxorubicin or doxorubicin
alone [37]. Patients who received Lactobacillus had a median survival of
232 days compared with 125 days in controls (p= 0.0061). However,
19 patients were excluded from the ﬁnal analysis, generating a high risk
of attrition bias. Interestingly, no further trials were undertaken using
either Lactobacillus casei or Nocardia rubra despite these seemingly
positive results.
The ﬁnal RCT investigated Corynebacterium parvum by randomising
21 participants to either Corynebacterium or intra-pleural mustine [7].
No survival diﬀerence was seen in this small study, with mean survival
of 80 days for Corynebacterium and 86 for mustine. No information was
provided about the distribution of the data, so it is unclear whether use
of mean survival values was appropriate. Additionally, outcomes were
not speciﬁed a priori, generating potential reporting bias.
3.6. Results of individual studies – non-randomised studies
Two non-randomised studies evaluated BCG cell wall skeleton
(BCG-cws) alongside standard care in patients with lung cancer.
[48,49], The ﬁrst reported median survival of 10 months in 55 patients
treated with BCG-cws, compared with 6 months in 32 age-matched
historic controls (p= 0.016) [48]. The second presented patient-level
data for 13 patients with MPE given BCG-cws and 17 historic controls
[49]. These data were analysed by the reviewers to reveal median
Table 3
Table demonstrating risk of bias of included papers [7,13,36–38,41–44,47–50].
Red – high risk of bias, green – low risk of bias, yellow – unclear risk of bias.
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survival of 8 months in the BCG-cws group and 4 months in controls,
with a hazard ratio of 0.374 (95% CI 0.168-0.833, p= 0.016). How-
ever, both studies were at risk of selection bias, and the latter included a
greater proportion of women in the BCG-cws group, a factor known to
be associated with longer survival in lung cancer [50]. Additionally the
use of historic controls may have introduced confounding due to ad-
vances in care happening between the two periods.
Two observational studies investigated Corynebacterium parvum.
McLeod et al retrospectively analysed data from 67 patients with MPE
treated with Corynebacterium parvum or intra-pleural mustine at a
single UK centre [13]. Mean survival was 251 days in the Cor-
ynebacterium group compared with 119 days in the mustine group
(p < 0.01). However, 14 patients died within 30 days of treatment and
were excluded from the ﬁnal analysis, introducing attrition bias. Ad-
ditionally, patients who received mustine were treated prior to 1980,
whilst the majority of Corynebacterium patients were treated after this,
raising the possibility of temporal confounding. Furthermore, 6 patients
who failed pleurodesis with mustine were excluded from the analysis,
generating reporting bias.
Senyigit et al also investigated Corynebacterium parvum, but in pa-
tients with MPM [47]. They described 117 patients who received intra-
pleural Corynebacterium, oxytetracycline or nitrogen mustard. No sur-
vival diﬀerence was detected between the three groups, with mean
survival of 10 months in Corynebacterium patients, 11 months in oxy-
tetracycline patients and 9 months in patients treated with nitrogen
mustard. The study was at risk of attrition bias as 27 participants were
excluded from the ﬁnal analysis due to death, disease progression or
loss to follow up. In addition, time-to-event modelling was not em-
ployed for survival analysis and thus censored data was not taken into
account.
Shimizu and colleagues evaluated 32 patients with NSCLC treated
with either intra-pleural OK432 or cisplatin between 2000 and 2004
[41]. They found no diﬀerence in survival, with median survival of 14
weeks in OK432 patients and 18 weeks in the cisplatin cohort. How-
ever, the two groups were markedly dissimilar, with worse prognostic
characteristics in the OK432 group and less systemic chemotherapy
administered in this group too. These diﬀerences could have attenuated
a potential survival beneﬁt associated with OK432, although the lack of
observed survival diﬀerence is consistent with previous RCT data.
[38,42–44,46],
Finally, Ren and colleagues gave intra-pleural staphylococcus su-
perantigen (SSAg) to 14 patients with MPE secondary to NSCLC, six of
whom also received intra-venous SSAg. Outcomes were compared with
18 historic controls from up to 10 years earlier. Median survival was 7.9
months in SSAg patients, compared with 2 months in controls
(p= 0.0023), leading the authors to conclude that SSAg had anti-
neoplastic eﬀects. However, the study was vulnerable to a number of
confounding factors, mainly relating to the diﬀerences between the two
treatment groups. As well as the temporal divide between cases and
controls, controls were treated in the USA whilst cases were recruited
and treated in Japan. Diﬀerences in epidemiology, tumour and popu-
lation genetics, healthcare systems, and treatment approaches between
the 2 countries make interpretation diﬃcult.
3.7. Meta-regression
A greater proportion of non-randomised studies reported favourable
survival in the intervention group compared with RCTs (4/6; 66.7% vs
2/8; 25%) although this result was not statistically signiﬁcant
(p=0.227). More studies undertaken prior to 2000 were positive
compared with studies published after that date (4/8; 50% vs 1/6;
16.7%), and meta-regression supported this trend (odds ratio 0.88, 95%
CI 0.77–1.00, p= 0.051)). A greater proportion of studies involving
lung cancer patients were positive (4/6; 66.7%), compared to MPE
secondary to NSCLC (1/5; 20%), any tumour (1/2; 50%) or MPM (0/1;
0%), but this diﬀerence was not signiﬁcant (p= 0.467).
No speciﬁc bacterial product appeared more eﬀective, although
RCTs of Lactobacillus and Nocardia rubra were both positive, and BCG
cell wall skeleton yielded positive results in both non-randomised stu-
dies that utilised it. [37,45,48,49], OK432 was not associated with any
survival beneﬁt in 5 randomised and 1 non-randomised studies,
[38,41–44,46], although for one of those studies the comparator was
intra-venous chemotherapy, suggesting that OK432 may be as eﬀective
as standard treatment [44]. Corynebacterium parvum was associated
with longer survival in one non-randomised study [13], but no eﬀect in
2 others (1 randomised7 and 1 non-randomised58), whilst Staphylo-
coccus aureus superantigen was associated with longer survival in a
single observational study [36].
4. Discussion
This systematic review evaluating the eﬀect of intra-pleural bac-
terial products on survival in malignant pleural eﬀusions is the ﬁrst to
formally summarise the literature for this topic. The review revealed a
lack of high quality evidence, with all 14 studies suﬀering from high or
unclear risk of bias in at least one domain.
The methodologies and results of the included studies were highly
heterogeneous and consequently meta-analysis was not possible. Six
studies reported a survival beneﬁt associated with intra-pleural bac-
terial products, whilst eight found no diﬀerence. No speciﬁc agent ap-
peared more likely to be associated with a survival beneﬁt and no
particular underlying disease was more likely to respond to intra-
pleural bacteria. A higher proportion of non-randomised studies re-
ported positive results, suggesting selection bias may have aﬀected
these results.
4.1. Implications for practice & future research
The current literature does not support the use of intra-pleural
bacterial products as anti-neoplastic treatment in MPE.
There are several possible interpretations for the ﬁndings of this
review. Firstly, there may be no relationship between intra-pleural
bacterial products and survival. Alternatively, a relationship may exist,
but existing studies have failed to demonstrate it. Finally, the variety of
agents, doses and administration regimens used in the diﬀerent studies
may have
obscured a genuine eﬀect related to a single agent or speciﬁc dose.
With respect to the latter point, it is accepted that diﬀerent bacterial
species and strains elicit diﬀering degrees of immunological responses.
For example, gram positive and gram negative bacteria induce diﬀerent
patterns of cytokine release with varying, and sometimes opposing,
down-stream cellular responses [51,52]. Similarly diﬀerent bacterial
strains or preparations can have widely varying eﬀects. Therefore it is
plausible that the lack of consistent eﬀect for any single agent could be
a result of some studies, for example those with positive outcomes,
using one strain whilst negative studies used an alternative, less im-
munogenic strain or preparation. Additionally, doses and administra-
tion regimens varied, with optimal dosage unknown for all the bacterial
products studied. Apart from one randomised trial of OK432 [43], no
formal dose-ﬁnding studies have been published for any of the bacterial
agents. This could have resulted in the use of sub-therapeutic doses with
consequent apparent ineﬃcacy.
An alternative explanation is that the studies failed to detect an
existing eﬀect. Small sample sizes and the fact that survival tended to be
a secondary outcome measure meant that the majority of studies were
under-powered to detect diﬀerences in survival. In fact, several of
studies were pilot projects with no formal sample size calculation un-
dertaken. In the absence of meta-analysis, negative results from small
individual studies should be interpreted with caution.
Finally, it may be the case that bacterial products have no eﬀect on
survival, despite good evidence that they are eﬀective pleurodesis
agents [6]. A similar eﬀect was seen when chemotherapy agents were
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administered intra-pleurally in malignant eﬀusions – the drugs eﬀec-
tively caused pleurodesis but did not aﬀect the underlying cancer or
alter survival. [53–56], A possible explanation for this is that drugs
administered into the pleural cavity have limited absorption into the
systemic circulation. This has been shown to be the case with intra-
pleural ﬁbrinolytics in empyema. [57–59], Since most MPE arise as a
result of metastatic disease, with at least one tumour located anato-
mically distant from the pleura, the lack of systemic absorption fol-
lowing intra-pleural administration limits exposure of distal tumours to
the agent, hence eﬃcacy is reduced.
By this theory, intra-pleural drug administration could be an ef-
fective approach for localised tumours i.e. malignant pleural mesothe-
lioma (MPM). Delivering the drug directly into the pleural space would
result in high concentrations of the therapeutic agent in the precise area
where its activity is required, whilst simultaneously reducing the risk of
side eﬀects from systemic absorption [54]. [60], The only study to in-
vestigate intra-pleural bacterial products in MPM was negative, al-
though risk of bias was high across all domains [47]. In contrast, an
observational study reported longer survival in MPM patients who ex-
perienced pleural infection, compared with MPM patients without in-
fection [61]. Although the results of this small study should be inter-
preted cautiously, they raise the possibility that bacteria in the pleural
space may be associated with longer survival in MPM. Suitably-pow-
ered randomised trials are required to determine whether bacterial
products could be therapeutically useful in MPM.
BCG was associated with a survival beneﬁt in both studies that
employed it, although they were non-randomised and at high risk of
bias in several domains. This is in keeping with the established anti-
neoplastic eﬀect of intra-vesical BCG in bladder cancer. [28,62–66],
BCG also exerts a cytotoxic eﬀect in melanoma, inducing tumour re-
gression and signiﬁcant prolongation of survival following intra-le-
sional administration [67]. The exact mechanism of action is unknown,
but is likely to involve activation of CD4+ and CD8+T lymphocytes
and release of cytokines, such as interferon-gamma and tumour necrosis
factor [68–71]. On the basis of its activity in other tumour-types, BCG
warrants further investigation and, since it appears to be eﬀective as a
topical treatment for localised tumours, MPM is a conceptual ﬁt as a
potential target disease.
4.2. Limitations of study
The main limitation of this study was the quality of data available
for inclusion. The majority of studies were observational and therefore
at high risk of selection bias, and many were also retrospective, with an
associated risk of reporting bias.
MPE is a heterogeneous disease which includes a wide range of
patients, disease processes and treatment options. Several diﬀerent
bacterial products have been used in clinical trials, at diﬀerent doses
and regimens. As discussed above, as well as preventing meta-analysis,
this heterogeneity makes interpretation diﬃcult, particularly in terms
of evaluating the eﬀect of individual bacterial products in speciﬁc
disease processes.
Finally, ﬁve papers were not available for full text review, and a
further six did not report the outcomes of interest despite mentioning
them in the methodology. Attempts to contact the authors for raw data
were unsuccessful, perhaps unsurprisingly given almost 3 decades had
passed since publication in some cases. Missing papers and outcomes
raise the possibility that the review could be aﬀected by publication
bias.
5. Conclusion
This systematic review of the survival eﬀects of intra-pleural bac-
terial immunotherapy revealed a lack of good quality evidence, with
high or unclear risk of bias in at least one domain in all included stu-
dies. Suitably powered, well-designed, prospective randomised trials
are warranted to evaluate whether bacterial products could be of
therapeutic beneﬁt in pleural malignancy.
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